Exhibit 16.1

 

April 5, 2021

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) under Item 4.01 of its Form 8-K dated April 5, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) contained therein.

 

Very truly yours,

 

/s/ Marcum LLP

 

Marcum LLP